IP Verse

Novel Fgfr3 Fusion Product - EP2824181

The patent EP2824181 was granted to Astellas Pharma on Nov 14, 2018. The application was originally filed on Mar 7, 2013 under application number EP13757006A. The patent is currently recorded with a legal status of "Revoked".

EP2824181

ASTELLAS PHARMA
Application Number
EP13757006A
Filing Date
Mar 7, 2013
Status
Revoked
May 26, 2023
Grant Date
Nov 14, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BOULT WADE TENNANTAug 14, 2019BOULT WADE TENNANTADMISSIBLE
JAMES POOLEAug 12, 2019CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2008075068
DESCRIPTIONWO2010129509
SEARCHEP2821402
SEARCHWO2014018673
SEARCHWO2014071419

Non-Patent Literature (NPL) Citations (37) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BIOCHEMICAL JOURNAL, (2011), vol. 437, pages 199 - 213-
DESCRIPTION- BLOOD, (2002), vol. 100, pages 1579 - 1583-
DESCRIPTION- CANCER RESEARCH, (2001), vol. 61, pages 8371 - 8374-
DESCRIPTION- CLIN. CANCER RES., (2008), pages 4275 - 4283-
DESCRIPTION- CLIN. CANCER RES., (2009), pages 3143 - 3149-
DESCRIPTION- CLIN. CANCER RES., (2009), vol. 7L, no. 1, pages 9 - 7123-
DESCRIPTION- CLINICAL CANCER RESEARCH, (2011), vol. 17, pages 7451 - 7461-
DESCRIPTION- Clinical Oncology, JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY-
DESCRIPTION- CYTOKINE & GROWTH FACTOR REVIEW, (2005), vol. 16, pages 139 - 149-
DESCRIPTION- DRUG DES. DEVEL. THER., (2011), pages 471 - 485-
DESCRIPTION- GENOME RES., (1996), vol. 6, no. 10, page 986-
DESCRIPTION- HUM MOL GENET., (20130215), vol. 22, no. 4, pages 795 - 803-
DESCRIPTION- J CLIN INVEST., (20130201), vol. 123, no. 2, pages 855 - 865-
DESCRIPTION- J MOL BIOL, (1970), vol. 48, pages 443 - 453-
DESCRIPTION- J. MOL. DIAGN., (2012), pages 22 - 29-
DESCRIPTION- JOURNAL OF MEDICINAL CHEMISTRY, (2011), vol. 54, pages 7066 - 7083-
DESCRIPTION- MOL CANCER THER, (2011), vol. 1 0, pages 2200 - 2210-
DESCRIPTION- NAT MED., (20120212), vol. 18, no. 3, pages 375 - 7-
DESCRIPTION- NAT. METHODS., (2006), pages 995 - 1000-
DESCRIPTION- NATURE, (2007), pages 561 - 566-
DESCRIPTION- N. TERRETT ET AL., DRUG DISCOV. TODAY, (1999), vol. 4, no. 1, page 41-
DESCRIPTION- ONCOGENE, (2009), vol. 28, pages 4306 - 4316-
DESCRIPTION- SCIENCE, (20120726), vol. 337, no. 6099, pages 1231 - 5-
DESCRIPTION- TRENDS IN CELL BIOLOGY, (2008), vol. 18, pages 379 - 388-
INTERNATIONAL-SEARCH-REPORT- AVET-LOISEAU H. ET AL., "High incidence of translocations t(11;14)(q13;q32) and t(4;14) (p16;q32) in patients with plasma cell malignancies", CANCER RES., (1998), vol. 58, no. 24, pages 5640 - 5645, XP055160897-
INTERNATIONAL-SEARCH-REPORT- YAGASAKI F. ET AL., "Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12) (p16;p13) chromosomal translocation", CANCER RES., (2001), vol. 61, no. 23, pages 8371 - 8374, XP055160898-
INTERNATIONAL-SEARCH-REPORT- GREULICH H. ET AL., "Targeting mutant fibroblast growth factor receptors in cancer", TRENDS MOL. MED., (2011), vol. 17, no. 5, pages 283 - 292, XP028206232
INTERNATIONAL-SEARCH-REPORT- SODERBERG 0. ET AL., "Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay", METHODS, (2008), vol. 45, no. 3, pages 227 - 232, XP023437838
INTERNATIONAL-SEARCH-REPORT- NILSSON I. ET AL., "VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts", EMBO J., (2010), vol. 29, no. 8, pages 1377 - 1388, XP055160883
INTERNATIONAL-SEARCH-REPORT- JARVIUS M. ET AL., "In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method", MOL. CELL. PROTEOMICS, (2007), vol. 6, no. 9, pages 1500 - 1509, XP002635677
INTERNATIONAL-SEARCH-REPORT- WILLIAMS SV. ET AL., "Oncogenic FGFR3 gene fusions in bladder cancer.", HUM. MOL. GENET., (20130215), vol. 22, no. 4, pages 795 - 803, XP055105338
INTERNATIONAL-SEARCH-REPORT- SOMAIAH N. ET AL., "Molecular targeted agents and biologic therapies for lung cancer", J. THORAC. ONCOL., (2011), vol. 6, pages 1758 - 1785, XP055160896
INTERNATIONAL-SEARCH-REPORT- SINGH D. ET AL., "Transforming fusions of FGFR and TACC genes in human glioblastoma", SCIENCE, (20120907), vol. 337, no. 6099, pages 1231 - 1235, XP055127902
INTERNATIONAL-SEARCH-REPORT- ZHAO G. ET AL., "A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models", MOL. CANCER THER., (2011), vol. 10, no. 11, pages 2200 - 2210, XP055160880
INTERNATIONAL-SEARCH-REPORT- PARKER BC. ET AL., "The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma", J. CLIN. INVEST., (20130201), vol. 123, no. 2, pages 855 - 865, XP055127845
OPPOSITION- KIEMENEY et al., "A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer", Nat. Genet., (20100000), vol. 42, no. 5, doi:10.1038/ng.558, XP055705010
OPPOSITION- STURLA et al., "FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells", Br. J. Cancer, (20030000), vol. 89, doi:10.1038/sj.bjc.6601249, pages 1276 - 1284, XP055073419

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents